Breaking News Instant updates and real-time market news.

TNXP

Tonix Pharmaceuticals

$3.85

0.85 (28.33%)

07:19
11/04/19
11/04
07:19
11/04/19
07:19

Tonix announces 12-week primary endpoint for Phase 3 RECOVERY study

Tonix Pharmaceuticals Holding announced that in the currently-enrolling Phase 3 study of Tonmya for the treatment of posttraumatic stress disorder, the timing of the primary endpoint analysis has been changed from Week 4 to Week 12 and the Company plans to add an interim analysis that allows for a potential sample size adjustment, based on guidance from its recent Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration. The Phase 3 study design changes are being implemented after the FDA indicated the importance of showing persistence of treatment effect at Week 12 in a pivotal study. In the revised protocol, the primary endpoint, mean change from baseline in the severity of PTSD symptoms as measured by the Clinician-Administered PTSD Scale for DSM-5, will be assessed at Week 12 instead of Week 4. Week 12 measurement of CAPS-5 was the same timepoint measurement used for the primary endpoint in the previous Phase 3 HONOR and the Phase 2 AtEase studies of Tonmya for PTSD. In addition, the RECOVERY study will include an unblinded interim analysis that allows for a potential sample size re-estimation. It will be conducted when 50 percent of the current target number of participants are randomized and have either completed or discontinued the 12-week course of treatment with bedtime Tonmya or placebo sublingual tablets. The introduction of the potential sample size re-estimation was added to address the potential impact of more drop-outs between Week 4 and Week 12, since the study was originally powered for a Week 4 endpoint. The data will be reviewed by an Independent Data Monitoring Committee which will make a non-binding recommendation to the Company based on the unblinded interim analysis. Pending final approval by FDA, the planned interim analysis will have three possible recommendations: 1) keep the current sample size and continue as planned; 2) provide the opportunity to increase the sample size to include up to a maximum of 120 additional participants, based on certain criteria; and 3) stop the study early for futility. The proposed design will not include an option to stop for positive efficacy at the interim analysis. The proposed sample size re-estimation methodology maintains the statistical hurdle of p less than 0.05. If the current sample size is kept at 250 participants at the interim analysis, there will be no statistical penalty on average compared to the current design. With an increase in sample size, the results from the cohorts before and after the interim analysis will be averaged with equal weight and p less than 0.05 will still be required for success. This methodology has been successfully utilized in other pivotal studies and was a component of the Phase 3 HONOR study's interim analysis that was agreed to by the FDA. Since more than 125 participants have already been enrolled, the Company expects to report the results of the interim analysis and the recommendation of the IDMC in the first quarter of 2020. If the current projected population of 250 study participants remains unchanged, the Company expects to report topline data in the second quarter of 2020.

TNXP Tonix Pharmaceuticals
$3.85

0.85 (28.33%)

04/18/19
ROTH
04/18/19
UPGRADE
ROTH
Buy
Tonix Pharmaceuticals upgraded to Buy from Neutral at Roth Capital
04/18/19
04/18/19
UPGRADE
Target $4

Buy
Tonix Pharmaceuticals upgraded to Buy at Roth Capital
As previously reported, Roth Capital analyst Scott Henry upgraded Tonix Pharmaceuticals to Buy from Neutral given that the company is attempting its third shot at the PTSD indication with the RECOVERY trial, enrollment adjustments give the trial a "reasonable shot at success," the cash runway could get the company to the key PTSD data readout in the first half of 2020, and the stock looks interesting using only a about 20% chance at approval. The analyst also raised his price target on the shares to $4 from 75c.
08/30/19
ROTH
08/30/19
NO CHANGE
Target $1.3
ROTH
Buy
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
Roth Capital analyst Scott Henry lowered his price target for Tonix Pharmaceuticals to $1.30 from $4.00 while maintaining a Buy rating on the shares. While dilution from the company's equity offering in July was "painful," it should have enough cash runway into a data release, Henry tells investors in a research note.

TODAY'S FREE FLY STORIES

EMR

Emerson

$75.75

1.21 (1.62%)

06:33
12/12/19
12/12
06:33
12/12/19
06:33
Initiation
Emerson initiated  »

Emerson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VERU

Veru

$2.47

0.17 (7.39%)

06:33
12/12/19
12/12
06:33
12/12/19
06:33
Earnings
Veru reports Q4 EPS (5c), consensus (5c) »

Reports Q4 revenue $8.7M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TRKNY

Turk Telekom

$0.00

(0.00%)

06:31
12/12/19
12/12
06:31
12/12/19
06:31
Downgrade
Turk Telekom rating change  »

Turk Telekom downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKZOY

AkzoNobel

$0.00

(0.00%)

06:30
12/12/19
12/12
06:30
12/12/19
06:30
Upgrade
AkzoNobel rating change  »

AkzoNobel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGNX

Cognex

$52.45

1.51 (2.96%)

06:30
12/12/19
12/12
06:30
12/12/19
06:30
Initiation
Cognex initiated  »

Cognex initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COLD

Americold Realty Trust

$35.03

-0.66 (-1.85%)

, INVH

Invitation Homes

$29.46

-0.42 (-1.41%)

06:29
12/12/19
12/12
06:29
12/12/19
06:29
Recommendations
Americold Realty Trust, Invitation Homes analyst commentary  »

Citi adds Americold…

COLD

Americold Realty Trust

$35.03

-0.66 (-1.85%)

INVH

Invitation Homes

$29.46

-0.42 (-1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSG

Wanda Sports

$2.82

-0.01 (-0.35%)

06:28
12/12/19
12/12
06:28
12/12/19
06:28
Downgrade
Wanda Sports rating change  »

Wanda Sports downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$57.32

-1.895 (-3.20%)

, SPNE

SeaSpine

$12.00

-0.58 (-4.61%)

06:27
12/12/19
12/12
06:27
12/12/19
06:27
Downgrade
Glaukos, SeaSpine, Merit Medical, Medtronic, Teleflex rating change  »

SeaSpine, Glaukos…

GKOS

Glaukos

$57.32

-1.895 (-3.20%)

SPNE

SeaSpine

$12.00

-0.58 (-4.61%)

MMSI

Merit Medical

$29.99

0.69 (2.35%)

MDT

Medtronic

$111.67

0.62 (0.56%)

TFX

Teleflex

$354.93

1.18 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

REG

Regency Centers

$62.65

-1.6 (-2.49%)

06:27
12/12/19
12/12
06:27
12/12/19
06:27
Downgrade
Regency Centers rating change  »

Regency Centers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRI

Weingarten Realty

$31.03

-0.41 (-1.30%)

06:26
12/12/19
12/12
06:26
12/12/19
06:26
Upgrade
Weingarten Realty rating change  »

Weingarten Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLCE

Children's Place

$54.36

-16.31 (-23.08%)

06:25
12/12/19
12/12
06:25
12/12/19
06:25
Downgrade
Children's Place rating change  »

Children's Place…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

O

Realty Income

$74.56

-1.08 (-1.43%)

06:24
12/12/19
12/12
06:24
12/12/19
06:24
Upgrade
Realty Income rating change  »

Realty Income upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADC

Agree Realty

$70.90

-1.34 (-1.85%)

06:23
12/12/19
12/12
06:23
12/12/19
06:23
Upgrade
Agree Realty rating change  »

Agree Realty upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICI

VICI Properties

$24.70

-0.17 (-0.68%)

06:22
12/12/19
12/12
06:22
12/12/19
06:22
Upgrade
VICI Properties rating change  »

VICI Properties upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDR

UDR, Inc.

$46.80

-0.95 (-1.99%)

06:21
12/12/19
12/12
06:21
12/12/19
06:21
Upgrade
UDR, Inc. rating change  »

UDR, Inc. upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DOC

Physicians Realty Trust

$18.64

-0.35 (-1.84%)

06:19
12/12/19
12/12
06:19
12/12/19
06:19
Upgrade
Physicians Realty Trust rating change  »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

HR

Healthcare Realty Trust

$32.85

-0.59 (-1.76%)

06:18
12/12/19
12/12
06:18
12/12/19
06:18
Upgrade
Healthcare Realty Trust rating change  »

Healthcare Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,749.00

9.85 (0.57%)

06:18
12/12/19
12/12
06:18
12/12/19
06:18
Periodicals
Amazon sells children's smartwatches that are 'so easy to hack,' BI reports »

Amazon sells…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$0.00

(0.00%)

06:16
12/12/19
12/12
06:16
12/12/19
06:16
Periodicals
SoftBank Vision Fund managing partner to leave company, Business Insider says »

Praveen Akkiraju, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBIX

Neurocrine

$113.26

-0.32 (-0.28%)

06:15
12/12/19
12/12
06:15
12/12/19
06:15
Recommendations
Neurocrine analyst commentary  »

Neurocrine price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXAS

Exact Sciences

$85.16

-0.25 (-0.29%)

06:13
12/12/19
12/12
06:13
12/12/19
06:13
Hot Stocks
Exact Sciences announces new data supporting Oncotype DX Breast Recurrence Score »

Exact Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YETI

Yeti

$31.82

1.19 (3.89%)

06:12
12/12/19
12/12
06:12
12/12/19
06:12
Recommendations
Yeti analyst commentary  »

Piper highlights Yeti as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$35.23

0.13 (0.37%)

06:12
12/12/19
12/12
06:12
12/12/19
06:12
Hot Stocks
CEO of GM's Cruise unit hints at offering low-cost shared rides »

Dan Ammann, the former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

WST

West Pharmaceutical

$146.54

1.07 (0.74%)

06:11
12/12/19
12/12
06:11
12/12/19
06:11
Downgrade
West Pharmaceutical rating change  »

West Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LULU

Lululemon

$233.31

3.75 (1.63%)

06:09
12/12/19
12/12
06:09
12/12/19
06:09
Recommendations
Lululemon analyst commentary  »

Lululemon Q3 beat shows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.